

CERTIFICATE OF ANALYSIS

Product: **CANIVERM comprimate á 0,175 g**

Batch No.: **B018-04**

Expiry: **24.5.2023**


Date of production: **25.5.2021**

Results of analysis:

Tests	Release limits	Shelf-life limits	Results
Appearance	Light yellow tablets.		conforms
Content of original package	2 x 1 tbl., 6 x 1 tbl., 100 x 1 tbl.		conforms
Microbiological quality	It shall comply with Ph. Eur., Article 5.1.4.		conforms
Content of fenbendazole	35.625 – 39.375 mg/0.175 g		38.484 mg/0.175 g
Fenbendazole identity	Must comply.		conforms
Content of pyrantel embonate	34.2 – 37.8 mg/0.175 g		37.47 mg/0.175 g
Pyrantel identity	Must comply.		conforms
Content of praziquantel	11.875 – 13.125 mg/0.175 g		12.377 mg/0.175 g
Praziquantel identity	Must comply.		conforms
Weight uniformity of tablets	0.166 – 0.184 g		0.176 g
Impurities of fenbendazole			
- content of oxfendazole	max. 1.0 %		0.0 %
- any individual unidentified impurity	max. 1.0 %		0.9 %
- sum of impurities	max. 3.0 %		0.9 %
Impurities of pyrantel embonate			
- any individual unidentified impurity	max. 1.0 %		0.6 %
- sum of impurities	max. 3.0 %		0.6 %
Impurities of praziquantel			
- any individual unidentified impurity	max. 1.0 %		0.0 %
- sum of impurities	max. 3.0 %		0.0 %
Break down tablets	Must conform.		conforms

I certify that this product has been tested in the laboratories of Bioveta a.s. and has been found to meet specification requirements. Preparation is suitable with control regulations of the valid PN No. 317, spec.02.




12/7/2021
Mgr. Hana Nezvalová
HEAD of QC, QP